# AAX Biotech Appoints Sarah Fredriksson as CEO to Lead Commercial Scale-Up > AAX Biotech appointed Sarah Fredriksson as CEO effective November 1, 2026, as the Swedish antibody technology developer moves from validation to commercial scale-up. - Published: 2026-11-05T07:13:43+00:00 - Section: Leadership - Author: News Desk - URL: https://newsforagent.com/news/2026-11-05/aax-biotech-sarah-fredriksson-ceo - Source: [news.cision.com](https://news.cision.com/aax-biotech-ab/r/aax-biotech-appoints-sarah-fredriksson-as-ceo,c4420038) ## Key takeaways - Sarah Fredriksson became CEO of AAX Biotech on November 1, 2026, joining from Aqilion, where she was CEO. - Fredriksson founded Genovis and served as its CEO for 16 years, including taking it public on Nasdaq First North Growth Market. - Co-founder Daniel X Johansson continues as Chief Scientific Officer and board member, focusing on Opti-mAb and Seqitope. [AAX Biotech](https://akta.pro/company-profiles/0003c78/aax-biotech) AB appointed Sarah Fredriksson as Chief Executive Officer effective November 1, 2026, the company said in a [news.cision.com](https://news.cision.com/aax-biotech-ab/r/aax-biotech-appoints-sarah-fredriksson-as-ceo,c4420038) announcement on November 5, 2026. Fredriksson joins from Aqilion, where she served as CEO, and succeeds the leadership team at the Swedish antibody technology developer. ## Fredriksson's Path From Genovis to AAX Biotech Fredriksson brings more than 20 years of leadership experience in the life sciences. At Aqilion she built the team behind a drug discovery pipeline of four programs in immunology and inflammation, led the company's Series A financing and drove a business development strategy that delivered an in-licensing transaction and a significant preclinical out-licensing and research collaboration agreement. Earlier, Fredriksson founded Genovis, a provider of enzyme-based tools for the characterization of biologic drugs, and served as its CEO for 16 years, including taking the company public on Nasdaq First North Growth Market. She holds a PhD in protein engineering from Lund Institute of Technology and is a member of the Royal Swedish Academy of Engineering Sciences. Co-founder Daniel X Johansson continues as Chief Scientific Officer and member of the Board of Directors. "I look forward to continuing to drive our technology development together with Sarah and the team," Johansson said. "Being able to focus fully on advancing Opti-mAb® and Seqitope® to the next stage, while gaining a CEO with a proven track record of turning science into partnerships with global pharma, is exactly what the company needs now." Svante Ahlmkvist, Chair of the Board, said Fredriksson "has made the journey that lies ahead of us, from strong science to company building, financing and licensing deals with global pharma." ## AAX Biotech's Shift to Commercial Scale-Up The appointment marks AAX Biotech's transition from technology validation to commercial scale-up. Over the past year, the company's proprietary platforms have been selected for evaluation by global pharmaceutical companies, including Daiichi Sankyo, and are offered to biotech and pharma customers through partner Evitria. The company said the next priority is to convert this momentum into partnerships, licensing agreements and business models that generate long-term value. "The interest we already see from global pharma creates clear opportunities for early partnering deals and new business models," Fredriksson said. ## AAX Biotech's Funding and Partnership Record AAX Biotech secured investment from Trio Impact Invest AB in February 2026, the first deployment from the firm's impact fund, to scale Seqitope and Opti-mAb platform development and broaden industry partnerships, according to akta.pro [company records](https://akta.pro/company-data). The same records show a 7 MSEK funding round backed by new and existing investors including Life Science Invest (LSI Epsilon), Karolinska Institutet Holding, Northislet, HJKK Didrikson and Phase2Phase Biopharma Ventures, used to automate the Seqitope platform, expand project initiatives and grow the team. ## Daiichi Sankyo and Evitria Deals Preceded the CEO Change In August 2026, AAX Biotech and Daiichi Sankyo advanced their collaboration into an antibody program after an initial evaluation of the Opti-mAb technology, news.cision.com reported. In April 2026, AAX Biotech signed Evitria AG as a channel and reseller for Opti-mAb research licenses, according to akta.pro company records. In September 2026, AAX Biotech won the Nordic Star Pitch Competition at NLSDays 2026, receiving a 10,000 EUR cash prize and two tickets to next year's event, Notified reported. ## Companies in this story - [AAX Biotech company profile](https://akta.pro/company-profiles/0003c78/aax-biotech) · website: https://aaxbiotech.com --- News for Agent · https://newsforagent.com/llms.txt